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ABSTRACT  
Background: Cognitive dysfunction was found in 55-80% 
Neuropsychiatry Systemic Lupus Erythematosus (NPSLE) 
patients. Serious concern from clinicans was needed as its 
impact to patient’s quality of life. Disease activity is expected 
to be affecting patient’s cognitive function. Previous studies 
regarding correlation between disease activity and cognitive 
dysfunction showed various results. This study aimed to 
evaluate the correlation between disease activity and cognitive 
function in SLE patients. 
 
Methods: This study is an analytical cross-sectional 
study. Subjects were SLE patients at the rheumatology 
clinic of Dr. Hasan Sadikin Hospital Bandung during 
June-August 2017. Subject’s evaluations included 
disease activity assessment using SLE disease activity 
index-2K (SLEDAI-2K) and cognitive function 
assessment using MoCA-Ina test. Data were analyzed by 
using Spearman Rank correlation test. 
Results: Mean age of the subjects was 31 ± 8 years old, 
most of them were senior high school graduates (65.8 %) 
and median length of study was 12 years. Subject’s 
median duration of illness was 44 months. Their MoCA-Ina 
median score was 25, while SLEDAI-2K median score was 
6. Cognitive dysfunctions were found in more than half of 
subjects (52.63%), which memory domain (78.95%) was 
most frequently impaired. Most of subjects were patients 
with active SLE (63.2%). Correlation test showed there 
was no correlation between SLEDAI-2K score and MoCA-
Ina score (rs=0.023, p=0.445). 
 
Conclusion: There was no correlation 
between disease activity (SLEDAI-2K score) 
and cognitive function (MoCA-Ina score).  
Keywords: Cognitive dysfunction, MoCA-Ina, 
Systemic lupus erythematosus, SLEDAI-2K  
 
 
INTRODUCTION 
Systemic Lupus Erythematosus (SLE) mostly attacks 
women at in their reproductive age along with high 
mortality rates. Incidence of SLE was almost three 
times higher over the last four decades and it is mostly 
caused by earlier detection and improvement in 
diagnosing of SLE.1,2 SLE disease course is marked by 
an exacerbations and remissions, hence careful 
monitoring of the disease activity is needed. A 
comprehensive management 
 
 
including frequent assessment of disease activity may 
enable us to control disease’s progressivity, prevent its 
complications, and provide optimal therapies to each 
patient.3 SLE disease activity can be evaluated by using 
Systemic Lupus Erythematosus Disease Activity Index-
2000 (SLEDAI-2K), which is the most common 
instrument used to evaluate disease activity in clinical 
practice and research, as it proved to be valid and 
sensitive.4-6 SLEDAI-2K represents immunological and 
inflammatory state in the nine organ systems that 
involved in NPSLE, such as kidney, hematology, 
musculoskeletal, mucocutaneous, eyes, vasculitis, 
serositis and immunology. Higher SLEDAI-2K score 
shows the disease activity is more severe and more organ 
systems involved.7-8 
 
SLE is an autoimmune disease with a broad 
spectrum of clinical manifestations and involving 
multiorgan systems, including Neuropsychiatric 
Systemic Lupus Erythematosus (NPSLE), which 
contributes to increased mortality and morbidity, 
also decreased quality of life in SLE patients. 
Cognitive dysfunction had highest prevalence, and 
was found in 55 to 80% of NPSLE patients. 
Pathogenesis of cognitive dysfunction in SLE was 
still unknown, however several clinical association 
have been reported its correlation with cognitive 
dysfunction such as:9 (1) There was a correlation 
between decreased cognitive function and active 
NPSLE or previous NPSLE, (2) Psychological 
distress that affect cognitive performance,  
(3) There was correlation between cognitive 
impairment and some certain autoantibodies in the 
serum or cerebrospinal fluid or both. Possible roles 
for antibodies such as anti-phospholipid and anti-
NMDAR in the pathogenesis of cognitive 
dysfunction have been suggested, (4) In SLE 
patient with cognitive dysfunction, the cytokines  
(IL-1, IL-6, IL-10 and IF-γ) were increased in the 
hippocampus area. 
Several factors were expected to have an impact 
on cognitive dysfunction in SLE such as vascular 
injuries, neuron injuries caused by autoantibodies and 
cytokines, and metabolic effects. Antibodies that play 
roles in the pathogenesis of cognitive dysfunction 
were antiphospholipid antibody and 
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anti-NMDAR. In hypercoagulable state, antiphospholipid 
antibodies lead to ischemia in the brain tissue and anti-NMDAR 
antibodies are likely to cause injuries in the hippocampus, areas 
associated with learning process.10,11 Cytokines (IL-1, IL-6, IL-10 
and IFN-γ) involved in cognitive dysfunction. Previous studies 
showed the excessive expression of cytokine genes in the 
hippocampus. Those pro inflammatory cytokines could induce 
apoptosis of the neurons and are thought to drive autoantibody 
production in SLE.12,13 Cytokines are predisposing neuronal 
growth, differentiation and development, also causing changes in 
receptor phosphorylation in the cellular level, increasing 
intracellular calcium level, and disrupt millions of signal 
transduction cascades which affecting neuronal plasticity. In 
SLE, cytokines (IL-1, IL-6, IL-10 and IF-γ) were involved in 
induction and amplification process of the inflammation, also 
showed their influences to memory and learning function.13 
 
Our previous study showed that cognitive dysfunction 
was found in 50% SLE patients, as memory domain was the 
most frequently impaired among other cognitive domains.10 In 
other study, most of cognitive domains were memory 
impairment, attention deficits, problem solving difficulties, 
poor decision making abilities. An early screening is needed 
as cognitive dysfunction does have an impact to patients’s 
quality of life, decreased work productivity and patient 
compliance.14,15  
Indonesian version of Montreal Cognitive Assessment 
(MoCA-Ina) has been validated and commonly used as a rapid 
screening instrument for detecting cognitive dysfunction in 
Indonesia. It also has high sensitivity and specificity to assess 
cognitive function in adult. MoCA-Ina assesses multiple 
cognitive domains including attention and concentration, 
excecutive function, memory, language, visuospatial skills, 
conceptual thinking, and orientation.16,17  
Regarding therapy and prognosis, correlation between 
disease activity and cognitive function is remarkable, however 
former studies showed various results.18-21 This study aimed to 
evaluate the correlation between SLE disease activity based 
on SLEDAI-2K score and cognitive function based on 
MoCA-Ina score in SLE patients. 
 
METHODS 
This is an analytical cross-sectional study. Subjects were SLE 
outpatients at the Rheumatology Clinic of Dr. Hasan Sadikin 
Hospital Bandung during June to August 2017. The evaluation 
included disease activity assessment using SLE disease 
activity index-2K (SLEDAI-2K) and cognitive function 
assessment using MoCA-Ina test.  
Consecutive data collection was carried out at 
Rheumatology Clinic and Memory Clinic Dr. Hasan Sadikin 
Hospital Bandung from June to August 2017. Subjects who 
fulfilled criteria of anxiety disorder or moderate to severe 
depression using Beck anxiety inventory (BAI) and Beck 
depression inventory (BDI) questionnaires were excluded 
from this study. All eligible subjects were evaluated by using 
SLEDAI-2K score for disease activity and MoCA-Ina test for 
cognitive function. Data were analyzed using Rank Spearman 
correlation test. 
 
 
RESULTS  
 
Table1. Characteristics of the subjects  
Characteristic n=38 
Age (years), mean ± SD 31 ± 8 
Level of education, n (%)    
- Elementary school 2 (5,3) 
- Junior high school 7 (18,4) 
- Senior high school 25 (65,8) 
- Diploma (D1) 2 (5,3) 
- Bachelor (S1) 2 (5,3) 
Length of study, median (min – max) 12 (6 – 16) 
Occupation, n (%)    
- Housewife 26 (68,4) 
- Private employee 6 (15,8) 
- Kindergarten teacher 2 (5,3) 
- College student 2 (5,3) 
- Unemployed 2 (5,3) 
Disease duration (months), median (min – max) 44 (1 – 204) 
MoCA-Ina score, median (min – max) 25 (18 – 30) 
SLEDAI-2K score, median (min – max) 6 (0 – 23) 
 
Note: SD=Standar Deviation, n=frequency, %=percentage 
 
Mean age of the study subjects was 31 years old, most of 
them were senior high school graduate or equals (65,8 %) with 
median length of study was 12 years. Most subjects (68,4%) 
work as housewives. Subject’s median disease duration was 
44 months. Their cognitive function based on MoCA-Ina 
median score was 25, while disease activity based on 
SLEDAI-2K median score was 6. 
 
Table 2. Distribution of cognitive function assessment 
 
Cognitive function n =38 
   
Cognitively normal 18 (47.37%) 
Cognitively impaired 20 (52.63%) 
Impaired cognitive domain n=38 
Visuospatial 6 (15.79%) 
Executive function 26 (68.42%). 
Attention 17 (44.74%) 
Language 13 (34.21%) 
Memory 30 (78.95%) 
Orientation 3 (7.89%) 
 
Patient was considered having cognitive dysfunction if 
MoCA-Ina scores less then 26. Table 2 showed that most 
subjects (52.63%) had cognitively impaired. Based on 
impaired cognitive domain, memory domain (78.95%) was 
most frequently impaired, followed by executive function 
(68.42%). There were subjects who had low memory score 
despite the fact that they had normal total cognitive score 
(≥26). Hence, there were more subjects with memory 
impairment than subjects with global cognitive dysfunction. 
 
18 Indonesian Journal of Rheumatology 2019; Vol 11 No.1 
  
Table 3. Distribution of cognitive dysfunction (MoCA-
Ina) based on active and inactive SLE (SLEDAI-2K) 
 
  Cognitive function (MoCA-Ina)  
 
n=38 
Cognitive Normal cognitive 
p value  
dysfunction function    
  n=20 n=18  
SLEDAI-2K     
Active SLE 
24 13 (54.2%) 11 (45.8%) 
 
(score ≥ 3) 
 
   
0.804 
Inactive SLE 
   
14 7 (50.0%) 7 (50.0%) 
 
(score < 3) 
 
    
 
Table 4. Distribution of cognitive dysfunction (MoCA-
Ina) in SLE based on severe disease activity and mild to 
moderate disease activity (SLEDAI-2K) 
 
  Cognitive function (MoCA-Ina) 
 
n=24 
  
p value  Cognitive Normal cognitive 
  dysfunction function 
  n=13 n=11 
SLEDAI-2K     
Severe activity 
8 4 (50.0%) 4 (50.0%) 
 
(score 12-105) 
 
    
Mild-moderate   1.000 
activity 16 9 (56.2%) 7 (43.8%)  
(skor 3-11)     
 
According to statistical assessment using Chi Square Test 
found cognitive dysfunction both in active or inactive SLE 
and in severe disease activity or mild to moderate disease 
activity were not statistically significant (p>0.05).  
 
 
Rs= 0.023, p value= 0.445 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Scatter diagram between SLEDAI-2K score 
andMoCA-Ina score 
 
Notes: Correlation analysis using Spearman Rank test, 
significant if p<0.05 
 
Figure 1 showed correlation analysis by using Rank Spearman 
test with correlation coefficient 0,023 and p= 0,445 (p>0,05), 
thus there were no correlation between disease activity and 
cognitive function. 
Original Article 
 
Table 5. Correlation between age, disease duration, length of 
education, and cognitive function (MoCA-Ina score) 
 
 MoCA-Ina  
 Correlation coefficient (rs) p value 
Age -0,230 0,083 
Disease duration -0,035 0,418 
Length of education (years) 0,436 0,003* 
 
Notes: Correlation analysis using Spearman Rank test, 
significant if p<0.05  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Scatter diagram between length of 
education and MoCA-Ina score 
 
Table 5 and Figure 2 showed correlation analysis by using 
Rank Spearman test, results were: (1) There was a negative 
correlation tendency between age and cognitive function based on 
MoCA-Ina score (rs=-0.230, p=0.083), suggesting that the older 
the subjects were, the lower the MoCA-Ina score obtained, (2) 
There was no correlation between disease duration and cognitive 
function based on MoCA-Ina score, (3) There was a moderate 
positive correlation between subject’s length of education and 
cognitive function based on MoCA-Ina score (rs=0.436, 
p=0.003), suggesting that the longer the length of education was, 
the higher MoCA-Ina score obtained. 
 
DISCUSSION 
Cognitive function test results (Table 1 and 2) showed most 
subjects (52.63%) had cognitive dysfunction, as memory domain 
(78.95%) was the most frequently impaired domain, followed by 
excecutive function domain (68.42%). Similar to the study 
Anjalia et al reported 50% SLE patients had cognitive 
dysfunction, most of which (86.67%) had impaired memory 
domain.10 Adeli et al utilized Mini Mental State Examination 
(MMSE) as cognitive assessment tool, the results showed that 
cognitive dysfunction was found three times higher in SLE 
patients than in non SLE patients with the most frequent impaired 
domain were orientation and memory domain.22  
In study that used Phillipines version of MoCA, Allan et al 
also reported that no correlation between disease activity and 
cognitive function in SLE.18 This finding aligned with study 
by El-Shafey et al, in which cognitive dysfunction did not 
correlate with disease activity.19 In contrary with our 
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study, Maneeton et al reported there was a correlation between 
cognitive scores and disease activity at the time of diagnosis was 
made. However, in this study, Maneeton et al used cognitive 
score as results from cognitive function assessment by using 
MMSE, CDT and 5-IADL and the result were calculated with T 
score. Disease activity was assessed by using MexSledai, as 
methods and instruments affected study results.20 Conti et al 
published disease activity, anti phospholipid antibody, and 
chronic damage were associated with cognitive dysfunction in 
SLE. In that study, cognitive dysfunction was assessed by using 
Global Cognitive Dysfunction Score (GCDs), while disease 
activity and chronic damages were assessed by using SLEDAI-
2K and SLICC.21 Different methods and instruments that were 
used could lead to different results of the studies. There are 
several screening tools used in assessing cognitive dysfunction in 
SLE. MoCA and MMSE were the two most common screening 
tools used in assessing cognitive function, both in clinical 
practice and research study. In this study, MoCA-Ina was chosen 
as it has been validated and commonly used as a rapid screening 
instrument for detecting cognitive dysfunction in Indonesia. It 
also has higher sensitivity than MMSE, which can detect milder 
cognitive impairment better than MMSE. Clock Drawing Test 
(CDT) in MoCA-Ina is an instrument used in cognitive function. 
More cognitive domains are assessed in MoCA-Ina than other 
cognitive function screening tools. 16,17 
 
Table 5 presented correlation analysis by Rank Spearman 
test between subject’s age, disease duration, and length of 
education with cognitive function based on MoCA-Ina score. 
Data analysis obtained there was a negative correlation 
tendency (rs=-0.230, p=0.083) between subject’s age and 
cognitive function (MoCA-Ina score), this results aligned with 
previous study which reported cognitive functions, especially 
attention and memory domain,were affected by subject’s 
age.23 Our study showed no correlation between disease 
duration and cognitive function (MoCA-Ina score). Similarly, 
Said et al reported there was no correlation between cognitive 
dysfunction and disease duration in SLE, however this study 
used Wechsler Memory Scale to assess cognitive 
dysfunction.24 Study by El-Shafey et al. presented 
contradictive results in which disease duration had a weak 
correlation with cognitive functions that were assessed by 
using Trail Making Test (TMT) B (p value=0.049, with r 
coefficient =0.492), yet there was no correlation between 
disease duration and cognitive function that were assessed by 
using MoCA test and Trail Making Test (TMT) A.19  
The study results also showed that there was a moderate 
positive correlation between subject’s length of education and 
cognitive functions, which were assessed by MoCA-Ina test, 
suggesting that the longer the length of study was, the higher 
MoCA-Ina score (better cognitive function) obtained. 
Consistent with the study, El-Shafey et al. reported subjects 
who were above12 years old had better cognitive function 
(higher MoCA score) than those who were under 12 years old 
(p value=0.017 or p<0.05).19 
 
 
CONCLUSION 
There was no correlation between SLE disease activity 
(SLEDAI 2-K) and cognitive function (MoCA-Ina score). 
Further investigation regarding the influencing factors are 
needed. 
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